New Data from the Open-Label PLEO-CMT-FU Trial Shows SustainedBenefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type1A After 5 Years […]
Continue ReadingDr Liliane Massade – PNP22 nanoparticles are effective in treating mouse models of CMT 1A – YouTube In this presentation, […]
Continue ReadingPress Release Pharnext Announces PXT3003 for the Treatment of CharcotMarie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) […]
Continue Reading2019.08.30_PXT3003_US_FDA_EN
Continue ReadingCRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue ReadingLast Updated: Monday 25th November, 2019